RSV Infection study: Candidate vaccine vs AREXVY
Official title Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
ClinicalTrials.gov ID: NCT06843317
What this study is testing
What is SCB-1019T?
SCB-1019T is an investigational vaccine being studied for revaccination against respiratory syncytial virus (RSV) in older adults. It is designed to stimulate the immune system by presenting RSV pre-fusion protein subunits from two dominant strains.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will look at how safe the revaccine is, how well it is tolerated, and whether it triggers an immune response.
- Who it's for
- Healthy adults, usually older, who have previously received the AREXVY RSV vaccine.
- What's involved
- Participants will receive the SCB‑1019T vaccine and attend scheduled visits for safety checks and blood tests to measure immune response.
- Phase 1: an early, usually small safety study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 60 to 85. Healthy volunteers may be eligible.
You may be able to join if
- Male and female participants 60-85 years of age at the screening visit and who received AREXVY before.
- Individuals are willing and able to comply with study requirements, including all scheduled visits, vaccination, laboratory tests, and other study...
- Individuals willing and able to give an informed consent, prior to screening.
- Healthy participants as determined by medical history, physical examination, and clinical judgment of the investigator
You likely can't join if
- Acute disease or fever (≥38°C) at time of vaccination. Participants with a minor illness (mild diarrhea, mild upper respiratory infection) without...
- Recurrent or un-controlled neurological disorders or seizures.
- Serious or unstable chronic illnesses
- Any history of dementia or any medical condition that moderately or severely impairs cognition
- History of a severe adverse reaction associated with a vaccine or severe allergic reaction (e.g., anaphylaxis) to any component of the study...
The study team makes the final eligibility decision.
Where it is enrolling
- Phoenix, Arizona, United States
- Fort Myers, Florida, United States
- Lexington, Kentucky, United States
- Kansas City, Missouri, United States
- Knoxville, Tennessee, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 60 years to 85 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Phoenix, Arizona, United States; Fort Myers, Florida, United States; Lexington, Kentucky, United States; Kansas City, Missouri, United States; Knoxville, Tennessee, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.